Idiopathic Retinal Vasculitis, Aneurysms and Neuroretinitis: Clinical Improvement with Infliximab

Ocul Immunol Inflamm. 2023 Feb;31(2):437-444. doi: 10.1080/09273948.2022.2027466. Epub 2022 Jan 26.

Abstract

Purpose: Idiopathic retinal vasculitis, aneurysms and neuroretinitis is a rare vision-threatening condition. If untreated vision loss occurs due to complications of progressive retinal ischaemia including retinal neovascularisation, neovascular glaucoma and retinal exudation. Despite the proposed underlying inflammatory aetiology this condition demonstrates poor response to corticosteroid treatment. The aim was to describe two paediatric cases of idiopathic retinal vasculitis, aneurysms and neuroretinitis treated with infliximab.

Methods: Two case reports.

Results: Infliximab treatment led to resolution of aneurysmal dilatations and retinal vasculitis, and reversal of some retinal capillary non-perfusion.

Conclusion: Early infliximab treatment should be considered in cases of idiopathic retinal vasculitis, aneurysms and neuroretinitis.

Keywords: IRVAN; aneurysms and neuroretinitis; corticosteroid; idiopathic retinal vasculitis; infliximab; uveitis.

Publication types

  • Case Reports

MeSH terms

  • Aneurysm* / complications
  • Aneurysm* / diagnosis
  • Aneurysm* / drug therapy
  • Child
  • Chorioretinitis* / complications
  • Fluorescein Angiography
  • Humans
  • Infliximab / therapeutic use
  • Retinal Vasculitis* / complications
  • Retinal Vasculitis* / diagnosis
  • Retinal Vasculitis* / drug therapy
  • Retinitis* / diagnosis
  • Retinitis* / drug therapy

Substances

  • Infliximab